{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T12:23:33Z","timestamp":1774959813701,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019515","name":"Cerveau Technologies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019515","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>A new tau PET tracer [<jats:sup>18<\/jats:sup>F]MK-6240 has been developed; however, its dosimetry and pharmacokinetics have been published only for a European population. This study investigated the safety, radiation dosimetry, pharmacokinetics and biodistribution of [<jats:sup>18<\/jats:sup>F]MK-6240 in Japanese elderly subjects. Also, the pattern and extent of brain retention of [<jats:sup>18<\/jats:sup>F]MK-6240 in Japanese healthy elderly subjects and patients with Alzheimer\u2019s disease (AD) were investigated. These Japanese results were compared with previous reports on non-Japanese.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Three healthy elderly subjects and three AD patients were enrolled. Dynamic whole-body PET scans were acquired for up to 232\u00a0min after starting injection of [<jats:sup>18<\/jats:sup>F]MK-6240 (370.4\u2009\u00b1\u200927.0\u00a0MBq) for the former, while a dynamic brain scan was performed from 0 to 75\u00a0min post injection for the latter. For both groups, brain PET scans were conducted from 90 to 110\u00a0min post injection. Sequential venous blood sampling was performed to measure the radioactivity concentration in the whole blood and plasma as well as the percentages of parent [<jats:sup>18<\/jats:sup>F]MK-6240 and radioactive metabolites in plasma. Organ doses and effective doses were estimated using the OLINDA Ver.2 software. Standardized uptake value ratios (SUVRs) and distribution volume ratios (DVRs) by Logan reference tissue model (LRTM) were measured in eight brain regions using the cerebellar cortex as the reference. Blood tests, urine analysis, vital signs and electrocardiography were performed for safety assessments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>No adverse events were observed. The highest radiation doses were received by the gallbladder (257.7\u2009\u00b1\u200974.9\u00a0\u03bcGy\/MBq) and the urinary bladder (127.3\u2009\u00b1\u200911.7\u00a0\u03bcGy\/MBq). The effective dose was 26.8\u2009\u00b1\u20091.4 \u03bcSv\/MBq. The parent form ([<jats:sup>18<\/jats:sup>F]MK-6240) was metabolized quickly and was less than 15% by 35\u00a0min post injection. While no obvious accumulation was found in the brain of healthy subjects, focal accumulation of [<jats:sup>18<\/jats:sup>F]MK-6240 was observed in the cerebral cortex of AD patients. Regional SUVRs of the focal lesions in AD patients increased gradually over time, and the difference of SUVRs between healthy subjects and AD patients became large and stable at 90\u00a0min after injection. High correlations of SUVR and DVR were observed (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The findings supported safety and efficacy of [<jats:sup>18<\/jats:sup>F]MK-6240 as a tau PET tracer for Japanese populations. Even though the number of subjects was limited, the radiation dosimetry profiles, pharmacokinetics, and biodistribution of [<jats:sup>18<\/jats:sup>F]MK-6240 were consistent with those for non-Japanese populations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Japan Pharmaceutical Information Center ID, JapicCTI-194972.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12149-022-01808-7","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T20:25:48Z","timestamp":1669062348000},"page":"108-120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Dosimetry and efficacy of a tau PET tracer [18F]MK-6240 in Japanese healthy elderly and patients with Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"37","author":[{"given":"Akihito","family":"Ohnishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Ikari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Aita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuji","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Yamane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7520-0942","authenticated-orcid":false,"given":"Michio","family":"Senda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"key":"1808_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/BF00693783","volume":"73","author":"C Duyckaerts","year":"1987","unstructured":"Duyckaerts C, Brion J-P, Hauw J-J, Flament-Durand J. Quantitative assessment of the density of neurofibrillary tangles and senile plaques in senile dementia of the Alzheimer type. Comparison of immunocytochemistry with a specific antibody and Bodian\u2019s protargol method. Acta Neuropathol. 1987;73:167\u201370.","journal-title":"Acta Neuropathol"},{"key":"1808_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/0022-510X(90)90226-D","volume":"97","author":"C Duyckaerts","year":"1990","unstructured":"Duyckaerts C, Dela\u00e8re P, Hauw J-J, Abbamondi-Pinto AL, Sorbi S, Allen I, et al. Rating of the lesions in senile dementia of the Alzheimer type: concordance between laboratories. A European multicenter study under the auspices of EURAGE. J Neurol Sci. 1990;97:295\u2013323.","journal-title":"J Neurol Sci"},{"key":"1808_CR3","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/BF00687893","volume":"77","author":"P D\u00e8laere","year":"1989","unstructured":"D\u00e8laere P, Duyckaerts C, Brion JP, Poulain V, Hauw J-J. Tau, paired helical filaments and amyloid in the neocortex: a morphometric study of 15 cases with graded intellectual status in aging and senile dementia of Alzheimer type. Acta Neuropathol. 1989;77:645\u201353.","journal-title":"Acta Neuropathol"},{"key":"1808_CR4","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M","volume":"46","author":"CA McLean","year":"1999","unstructured":"McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of A\u03b2 amyloid as a determinant of severity of neurodegeneration in Alzheimer\u2019s disease. Ann Neurol. 1999;46:860\u20136.","journal-title":"Ann Neurol"},{"key":"1808_CR5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S1474-4422(14)70252-2","volume":"14","author":"VL Villemagne","year":"2015","unstructured":"Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14:114\u201324.","journal-title":"Lancet Neurol"},{"key":"1808_CR6","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","volume":"24","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, Chiotis K, Lemoine L, Gillberg P-G, Almkvist O, Rodriguez-Vieitez E, et al. Tau PET imaging in neurodegenerative tauopathies\u2014still a challenge. Mol Psychiatry. 2019;24:1112\u201334.","journal-title":"Mol Psychiatry"},{"key":"1808_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2967\/jnumed.118.208215","volume":"60","author":"TG Lohith","year":"2019","unstructured":"Lohith TG, Bennacef I, Vandenberghe R, Vandenbulcke M, Salinas CA, Declercq R, et al. Brain imaging of Alzheimer dementia patients and elderly controls with 18F-MK-6240, a PET tracer targeting neurofibrillary tangles. J Nucl Med. 2019;60:107\u201314.","journal-title":"J Nucl Med"},{"key":"1808_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11307-019-01367-w","volume":"22","author":"M Koole","year":"2020","unstructured":"Koole M, Lohith TG, Valentine JL, Bennacef I, Declercq R, Reynders T, et al. Preclinical safety evaluation and human dosimetry of [18F]MK-6240, a novel PET tracer for imaging neurofibrillary tangles. Mol Imaging Biol. 2020;22:173\u201380.","journal-title":"Mol Imaging Biol"},{"key":"1808_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/jlcr.3496","volume":"60","author":"TL Collier","year":"2017","unstructured":"Collier TL, Yokell DL, Livni E, Rice PA, Celen S, Serdons K, et al. cGMP production of the radiopharmaceutical [18F]MK-6240 for PET imaging of human neurofibrillary tangles. J Labelled Comp Radiopharm. 2017;60:263\u20139.","journal-title":"J Labelled Comp Radiopharm"},{"key":"1808_CR10","doi-asserted-by":"publisher","first-page":"5394","DOI":"10.1118\/1.3635220","volume":"38","author":"V Bettinardi","year":"2011","unstructured":"Bettinardi V, Presotto L, Rapisarda E, Picchio M, Gianolli L, Gilardi MC. Physical performance of the new hybrid PET\u2215CT discovery-690. Med Phys. 2011;38:5394\u2013411.","journal-title":"Med Phys"},{"key":"1808_CR11","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023\u20137.","journal-title":"J Nucl Med"},{"key":"1808_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40658-016-0159-y","volume":"3","author":"Y Ikari","year":"2016","unstructured":"Ikari Y, Akamatsu G, Nishio T, Ishii K, Ito K, Iwatsubo T, et al. Phantom criteria for qualification of brain FDG and amyloid PET across different cameras. EJNMMI Phys. 2016;3:23.","journal-title":"EJNMMI Phys"},{"key":"1808_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s12149-015-1024-0","volume":"30","author":"G Akamatsu","year":"2016","unstructured":"Akamatsu G, Ikari Y, Nishio T, Nishida H, Ohnishi A, Aita K, et al. Optimization of image reconstruction conditions with phantoms for brain FDG and amyloid PET imaging. Ann Nucl Med. 2016;30:18\u201328.","journal-title":"Ann Nucl Med"},{"key":"1808_CR14","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/00004647-199609000-00008","volume":"16","author":"J Logan","year":"1996","unstructured":"Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834\u201340.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1808_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/syn.21782","volume":"69","author":"AD Joshi","year":"2015","unstructured":"Joshi AD, Sanabria-Boh\u00f3rquez SM, Bormans G, Koole M, de Hoon J, van Hecken A, et al. Characterization of the novel GlyT1 PET tracer [18F]MK-6577 in humans. Synapse. 2015;69:33\u201340.","journal-title":"Synapse"},{"key":"1808_CR16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11307-015-0924-7","volume":"18","author":"JY Choi","year":"2016","unstructured":"Choi JY, Lyoo CH, Lee JH, Cho H, Kim KM, Kim JS, et al. Human radiation dosimetry of [18F]AV-1451(T807) to detect tau pathology. Mol Imaging Biol. 2016;18:479\u201382.","journal-title":"Mol Imaging Biol"},{"issue":"3\u20134","key":"1808_CR17","first-page":"1","volume":"32","author":"ICRP","year":"2002","unstructured":"ICRP. Basic anatomical and physiological data for use in radiological protection: reference values. ICRP publication 89. Ann ICRP. 2002;32(3\u20134):1\u2013277.","journal-title":"Ann ICRP"},{"key":"1808_CR18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13195-018-0402-y","volume":"10","author":"TA Pascoal","year":"2018","unstructured":"Pascoal TA, Shin M, Kang MS, Chamoun M, Chartrand D, Mathotaarachchi S, et al. In vivo quantification of neurofibrillary tangles with [18F]MK-6240. Alzheimers Res Ther. 2018;10:74.","journal-title":"Alzheimers Res Ther"},{"key":"1808_CR19","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1007\/s00259-019-04419-z","volume":"46","author":"NJ Guehl","year":"2019","unstructured":"Guehl NJ, Wooten DW, Yokell DL, Moon S-H, Dhaynaut M, Katz S, et al. Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [18F]MK6240 in human subjects. Eur J Nucl Med Mol Imaging. 2019;46:2099\u2013111.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1808_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2967\/jnumed.118.209650","volume":"60","author":"TJ Betthauser","year":"2019","unstructured":"Betthauser TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE, et al. In vivo characterization and quantification of neurofibrillary tau PET radioligand 18F-MK-6240 in humans from Alzheimer disease dementia to young controls. J Nucl Med. 2019;60:93\u20139.","journal-title":"J Nucl Med"},{"key":"1808_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239\u201359.","journal-title":"Acta Neuropathol"},{"key":"1808_CR22","first-page":"2083","volume":"41","author":"M Slifstein","year":"2000","unstructured":"Slifstein M, Laruelle M. Effects of statistical noise on graphic analysis of PET neuroreceptor studies. J Nucl Med. 2000;41:2083\u20138.","journal-title":"J Nucl Med"},{"key":"1808_CR23","doi-asserted-by":"publisher","first-page":"622","DOI":"10.2967\/jnumed.111.095927","volume":"53","author":"Y Zhou","year":"2012","unstructured":"Zhou Y, Sojkova J, Resnick SM, Wong DF. Relative equilibrium plot improves graphical analysis and allows bias correction of standardized uptake value ratio in quantitative 11C-PiB PET studies. J Nucl Med. 2012;53:622\u20138.","journal-title":"J Nucl Med"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-022-01808-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-022-01808-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-022-01808-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T08:08:43Z","timestamp":1675670923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-022-01808-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1808"],"URL":"https:\/\/doi.org\/10.1007\/s12149-022-01808-7","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,21]]},"assertion":[{"value":"25 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YI is an employee of CMIC Co., Ltd., Tokyo, Japan. HN is an employee of Micron, Inc., Tokyo, Japan. MS (Masahiro Sasaki) is an employee of Healthcare Innovation Technologies Japan (HIT\u2019s-J) Co., Ltd., Osaka, Japan. KA is currently an employee of PDRadiopharma Inc., Tokyo, Japan, and this work was performed at the Kobe City Medical Center General Hospital prior to his affiliation change. The authors declare that they have no other competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}